

CITATION REPORT

List of articles citing

Nonalcoholic fatty liver disease/steatohepatitis:
epidemiology, pathogenesis, clinical presentation and treatment

DOI: 10.1159/000336669

Digestive Diseases, 2012, 30, 158-62.

Source: <https://exaly.com/paper-pdf/53730746/citation-report.pdf>

Version: 2024-04-09

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
151	Update on ppar α and nonalcoholic Fatty liver disease. 2012 , 2012, 912351		32
150	Causative role of gut microbiota in non-alcoholic fatty liver disease pathogenesis. 2012 , 2, 132		36
149	Frequency and implication of focal fatty sparing in segmental homogeneous fatty liver at ultrasound. 2013 , 40, 393-8		1
148	Immune and inflammatory pathways in NASH. 2013 , 7 Suppl 2, 771-81		121
147	Nonalcoholic fatty liver disease and the metabolic syndrome: clinical implications and treatment. 2013 , 28, 40-51		46
146	Liver steatosis in Chinese HIV-infected patients with hypertriglyceridemia: characteristics and independent risk factors. 2013 , 10, 261		3
145	Phenotypic comparison of common mouse strains developing high-fat diet-induced hepatosteatosis. 2013 , 2, 435-46		44
144	The association between TCM syndromes and SCAP polymorphisms in subjects with non-alcoholic fatty liver disease. 2013 , 5, 386-392		2
143	Nuclear factor (erythroid-derived 2)-like-2 factor (Nrf2), a key regulator of the antioxidant response to protect against atherosclerosis and nonalcoholic steatohepatitis. 2013 , 13, 362-71		74
142	Glucose-dependent insulintropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas. 2013 , 4, 108-30		170
141	Role of the gastroenterologist in managing obesity. 2013 , 7, 439-51		21
140	Dual role of microRNAs in NAFLD. 2013 , 14, 8437-55		51
139	Findings and implications of focal fatty sparing of the liver at follow-up: a preliminary study based on sonography, computed tomography, and magnetic resonance imaging. 2013 , 32, 1695-702		1
138	Clinical characteristics and time trends in etiology of hepatocellular cancer in Germany. 2013 , 87, 147-59		27
137	Chronic kidney disease and nonalcoholic Fatty liver disease proven by transient elastography. 2013 , 37, 305-10		48
136	MicroRNAs as controlled systems and controllers in non-alcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2014 , 20, 15079-86	5.6	40
135	Meta-omic platforms to assist in the understanding of NAFLD gut microbiota alterations: tools and applications. 2014 , 15, 684-711		21

134	Role of mitochondria in nonalcoholic fatty liver disease. 2014 , 15, 8713-42	183
133	Endoplasmic reticulum stress in hepatic steatosis and inflammatory bowel diseases. 2014 , 5, 242	49
132	Inhibition of ceramide de novo synthesis reduces liver lipid accumulation in rats with nonalcoholic fatty liver disease. 2014 , 34, 1074-83	89
131	Chronic kidney disease and nonalcoholic Fatty liver disease-is there a link?. 2014 , 2014, 847539	40
130	4Ps medicine of the fatty liver: the research model of predictive, preventive, personalized and participatory medicine-recommendations for facing obesity, fatty liver and fibrosis epidemics. 2014 , 5, 21	24
129	Obesity-associated nonalcoholic fatty liver disease. 2014 , 18, 19-31	59
128	Splanchnic and Extrasplanchnic Thrombosis in Cirrhosis: Prophylaxis vs Treatment. 2014 , 13, 224-234	2
127	Nonalcoholic fatty liver disease (NAFLD) proven by transient elastography in patients with coronary heart disease. 2014 , 126, 474-9	11
126	Fast food diet with CCl4 micro-dose induced hepatic-fibrosis--a novel animal model. 2014 , 14, 89	17
125	Liver in the analysis of body composition by dual-energy X-ray absorptiometry. 2014 , 87, 20140232	6
124	Nonalcoholic Fatty liver disease in renal transplant recipients proven by transient elastography. 2014 , 46, 1347-52	10
123	Nonalcoholic fatty liver disease (NAFLD): a new risk factor for adverse cardiovascular events in dialysis patients. 2014 , 82, 205-8	21
122	Murine models provide insight to the development of non-alcoholic fatty liver disease. 2015 , 28, 133-142	17
121	GWAS-Identified Common Variants With Nonalcoholic Fatty Liver Disease in Chinese Children. 2015 , 60, 669-74	20
120	Nonalcoholic steatohepatitis: emerging targeted therapies to optimize treatment options. 2015 , 9, 4835-45	35
119	Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome. <i>World Journal of Gastroenterology</i> , 2015 , 21, 7860-8	5.6 97
118	Intravenous Mycobacterium Bovis Bacillus Calmette-Guérin Ameliorates Nonalcoholic Fatty Liver Disease in Obese, Diabetic ob/ob Mice. <i>PLoS ONE</i> , 2015 , 10, e0128676	3.7 7
117	Association Between the Severity of Nocturnal Hypoxia in Obstructive Sleep Apnea and Non-Alcoholic Fatty Liver Damage. <i>Hepatitis Monthly</i> , 2015 , 15, e32655	1.8 28

116	Lifestyle changes associated with a new antioxidant formulation in non-alcoholic fatty liver disease: a case series. 2015 , 14, 121-126	4
115	Prevalence of Nonalcoholic Fatty Liver Disease and Economy. 2015 , 60, 3194-202	72
114	The first Polish liver transplantation after Roux-en-Y gastric bypass surgery for morbid obesity: a case report and literature review. 2015 , 20, 112-5	7
113	Can NASH lipidome provide insight into the pathogenesis of obesity-related non-alcoholic fatty liver disease?. 2015 , 62, 761-2	6
112	Increased Plasma Levels of Asymmetric Dimethylarginine in Nonalcoholic Fatty Liver Disease: Relation With Insulin Resistance, Inflammation, and Liver Histology. 2015 , 63, 871-7	10
111	Hepatic PTEN deficiency improves muscle insulin sensitivity and decreases adiposity in mice. 2015 , 62, 421-9	37
110	Protopanaxatriol, a novel PPAR α antagonist from Panax ginseng, alleviates steatosis in mice. 2014 , 4, 7375	49
109	MicroRNAs in fatty liver disease. 2015 , 35, 12-25	28
108	Strategies, models and biomarkers in experimental non-alcoholic fatty liver disease research. 2015 , 59, 106-25	100
107	Effects of Mediterranean diet supplemented with silybin-vitamin E-phospholipid complex in overweight patients with non-alcoholic fatty liver disease. 2015 , 9, 519-27	63
106	Nonalcoholic fatty liver disease induced by 13-week oral administration of 1,3-dichloro-2-propanol in C57BL/6J mice. 2015 , 39, 1115-21	3
105	CYP2J2 overexpression attenuates nonalcoholic fatty liver disease induced by high-fat diet in mice. 2015 , 308, E97-E110	33
104	Combining metformin therapy with caloric restriction for the management of type 2 diabetes and nonalcoholic fatty liver disease in obese rats. 2015 , 40, 1038-47	27
103	Quantitative analysis of the murine lipid droplet-associated proteome during diet-induced hepatic steatosis. 2015 , 56, 2260-72	45
102	Plasma Pentraxin 3 Differentiates Nonalcoholic Steatohepatitis (NASH) from Non-NASH. 2015 , 13, 393-9	16
101	Nonalcoholic fatty liver disease - current status and future directions. 2015 , 16, 541-57	61
100	The Role of Iron and Iron Overload in Chronic Liver Disease. <i>Medical Science Monitor</i> , 2016 , 22, 2144-51	3.2 79
99	Autophagy: a new target for nonalcoholic fatty liver disease therapy. 2016 , 8, 27-37	70

98	. 2016 ,	2
97	Host factors are dominant in the development of post-liver transplant non-alcoholic steatohepatitis. <i>World Journal of Hepatology</i> , 2016 , 8, 659-64	3-4 3
96	Is NAFLD different in absence of metabolic syndrome?. 2016 , 44-49	
95	Endoplasmic reticulum stress related molecular mechanisms in nonalcoholic steatohepatitis. 2016 , 157, 17-29	52
94	Global Epidemiology of Nonalcoholic Fatty Liver Disease and Perspectives on US Minority Populations. 2016 , 61, 1214-25	98
93	Lipid-Induced Endoplasmic Reticulum Stress Impairs Selective Autophagy at the Step of Autophagosome-Lysosome Fusion in Hepatocytes. 2016 , 186, 1861-1873	53
92	The Effects of Metabolic Surgery on Fatty Liver Disease and Nonalcoholic Steatohepatitis. 2016 , 96, 703-15	16
91	Interaction between periodontitis and liver diseases. 2016 , 5, 267-276	39
90	Role of NCAN rs2228603 polymorphism in the incidence of nonalcoholic fatty liver disease: a case-control study. 2016 , 15, 207	1
89	The unfolded protein response in immunity and inflammation. 2016 , 16, 469-84	385
88	Role of Lipogenesis and Lipid Desaturases in Non-alcoholic Fatty Liver Disease. 2016 , 143-164	
87	Obesity: An overview of possible role(s) of gut hormones, lipid sensing and gut microbiota. 2016 , 65, 48-65	101
86	Comparison of the Phenotype and Approach to Pediatric vs Adult Patients With Nonalcoholic Fatty Liver Disease. 2016 , 150, 1798-810	84
85	The rationale for targeting TGF- β in chronic liver diseases. 2016 , 46, 349-61	46
84	Pathogenesis of nonalcoholic steatohepatitis. 2016 , 73, 1969-87	111
83	Hepatic De Novo Lipogenesis and Regulation of Metabolism. 2016 ,	3
82	Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach. 2017 , 65, 451-464	354
81	Modified thresholds for fibrosis risk scores in nonalcoholic fatty liver disease are necessary in the obese. 2017 , 27, 115-125	19

80	Ginkgolide A ameliorates non-alcoholic fatty liver diseases on high fat diet mice. 2017 , 88, 625-634		33
79	Hepatic DsbA-L protects mice from diet-induced hepatosteatosis and insulin resistance. 2017 , 31, 2314-2326		17
78	Hepatic anti-inflammatory effect of hexane extracts of <i>Dioscorea batatas</i> Decne: Possible suppression of toll-like receptor 4-mediated signaling. 2017 , 92, 157-167		2
77	Effect of Gangjihwan on hepatic steatosis and inflammation in high fat diet-fed mice. 2017 , 206, 315-326		11
76	Probiotics may delay the progression of nonalcoholic fatty liver disease by restoring the gut microbiota structure and improving intestinal endotoxemia. 2017 , 7, 45176		131
75	Phyllanthus Niruri Standardized Extract Alleviates the Progression of Non-Alcoholic Fatty Liver Disease and Decreases Atherosclerotic Risk in Sprague-Dawley Rats. <i>Nutrients</i> , 2017 , 9,	6.7	27
74	Dahuang Zexie Decoction Protects against High-Fat Diet-Induced NAFLD by Modulating Gut Microbiota-Mediated Toll-Like Receptor 4 Signaling Activation and Loss of Intestinal Barrier. 2017 , 2017, 2945803		14
73	Natural products berberine and curcumin exhibited better ameliorative effects on rats with non-alcohol fatty liver disease than lovastatin. 2018 , 99, 325-333		27
72	Concomitant nonalcoholic fatty liver disease does not alter the activity, severity or course of primary biliary cholangitis. 2018 , 38, 1110-1116		5
71	Swimming, but not vitamin E, ameliorates prothrombotic state and hypofibrinolysis in a rat model of nonalcoholic fatty liver disease. 2018 , 29, 61-71		6
70	HCBP6 Is Involved in the Development of Hepatic Steatosis Induced by High-Fat Diet and CCL4 in Rats. 2018 , 17, 511-518		3
69	Mori Cortex extract ameliorates nonalcoholic fatty liver disease (NAFLD) and insulin resistance in high-fat-diet/streptozotocin-induced type 2 diabetes in rats. 2018 , 16, 411-417		6
68	Changes in peroxisome proliferator-activated receptor alpha target gene expression in peripheral blood mononuclear cells associated with non-alcoholic fatty liver disease. 2018 , 17, 256		7
67	Comparative effects of vitamin D and vitamin C supplementations with and without endurance physical activity on metabolic syndrome patients: a randomized controlled trial. 2018 , 10, 80		7
66	Oxidative Stress and Nonalcoholic Fatty Liver Disease in Hemodialysis Patients. 2018 , 2018, 3961748		6
65	Microbial Intervention as a Novel Target in Treatment of Non-Alcoholic Fatty Liver Disease Progression. 2018 , 51, 2123-2135		19
64	Advanced Liver Fibrosis Is Independently Associated with Palmitic Acid and Insulin Levels in Patients with Non-Alcoholic Fatty Liver Disease. <i>Nutrients</i> , 2018 , 10,	6.7	23
63	The Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease. 2018 , 6,		10

62	Increased butyrate priming in the gut stalls microbiome associated-gastrointestinal inflammation and hepatic metabolic reprogramming in a mouse model of Gulf War Illness. <i>Toxicology and Applied Pharmacology</i> , 2018 , 350, 64-77	4.6	36
61	Dynamic PET of human liver inflammation: impact of kinetic modeling with optimization-derived dual-blood input function. 2018 , 63, 155004		14
60	Enzymatic and nonenzymatic protein acetylations control glycolysis process in liver diseases. 2019 , 33, 11640-11654		8
59	Obesity, adipocyte hypertrophy, fasting glucose, and resistin are potential contributors to nonalcoholic fatty liver disease in South Asian women. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2019 , 12, 863-872	3.4	6
58	Development of liver surface nodularity quantification program and its clinical application in nonalcoholic fatty liver disease. 2019 , 9, 9994		7
57	The anti-inflammatory potential of diet and nonalcoholic fatty liver disease: the ATTICA study. 2019 , 12, 1756284819858039		9
56	Accuracy of proton magnetic resonance for diagnosing non-alcoholic steatohepatitis: a meta-analysis. 2019 , 9, 15002		7
55	Molecular insights into the role of mitochondria in non-alcoholic fatty liver disease. 2019 , 42, 935-946		51
54	Ultrasound/Elastography techniques, lipidomic and blood markers compared to Magnetic Resonance Imaging in non-alcoholic fatty liver disease adults. 2019 , 16, 75-83		16
53	Blond and blood juice supplementation in high fat diet fed mice: effect on antioxidant status and DDAH/ADMA pathway.. 2019 , 9, 11406-11412		1
52	Comprehensive circular RNA expression profiles in a mouse model of nonalcoholic steatohepatitis. 2019 , 19, 2636-2648		7
51	Quantitative magnetic resonance imaging evaluation of hepatic fat content with iron deposition: will it be disturbed?. <i>Journal of International Medical Research</i> , 2019 , 47, 1958-1974	1.4	6
50	Ethnic differences and heterogeneity in genetic and metabolic makeup contributing to nonalcoholic fatty liver disease. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2019 , 12, 357-367	3.4	18
49	High-fat diet aggravates the liver disease caused by periodontitis in rats. <i>Journal of Periodontology</i> , 2019 , 90, 1023-1031	4.6	10
48	Frequency of metabolic syndrome among newly detected type 2 diabetic patients with non-alcoholic fatty liver disease and high serum alanine aminotransferase levels. <i>BIRDEM Medical Journal</i> , 2019 , 10, 21-25	0.1	
47	Association between Helicobacter pylori infection and nonalcoholic fatty liver: A meta-analysis. <i>Medicine (United States)</i> , 2019 , 98, e17781	1.8	15
46	Effect of lifestyle modification education based on health belief model in overweight/obese patients with non-alcoholic fatty liver disease: A parallel randomized controlled clinical trial. <i>Clinical Nutrition ESPEN</i> , 2020 , 38, 236-241	1.3	7
45	Association Between Non-Alcoholic Fatty Liver Disease and Metabolic Syndrome with Gallstone Disease, South Iran : A Population-Based Study. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2020 , 13, 1449-1458	3.4	5

44	Effects of L. Seeds and Juice on Liver Steatosis in an Animal Model of Diet-Induced Obesity. <i>Nutrients</i> , 2020 , 12,	6.7	6
43	Baicalin and its nanoliposomes ameliorates nonalcoholic fatty liver disease via suppression of TLR4 signaling cascade in mice. <i>International Immunopharmacology</i> , 2020 , 80, 106208	5.8	13
42	Clinical profile of non-alcoholic fatty liver disease in nonobese patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021 , 36, 257-261	4	0
41	A randomized controlled clinical trial comparing calcitriol versus cholecalciferol supplementation to reduce insulin resistance in patients with non-alcoholic fatty liver disease. <i>Clinical Nutrition</i> , 2021 , 40, 2999-3005	5.9	5
40	Oscillating lncRNA regulates inflammasome to ameliorate nonalcoholic steatohepatitis in mice. <i>Theranostics</i> , 2021 , 11, 426-444	12.1	7
39	Assessment of the association between body composition and risk of non-alcoholic fatty liver. <i>PLoS ONE</i> , 2021 , 16, e0249223	3.7	1
38	Integrated Action of Autophagy and Adipose Tissue Triglyceride Lipase Ameliorates Diet-Induced Hepatic Steatosis in Liver-Specific PLIN2 Knockout Mice. <i>Cells</i> , 2021 , 10,	7.9	3
37	Predicting risk of erectile dysfunction in patients with nonalcoholic fatty liver disease. <i>Andrologia</i> , 2021 , 53, e14091	2.4	0
36	"Dental Cluster" Versus "Metabolic Cluster": Analyzing the Associations of Planned and Delivered Dental Procedures with Metabolic Syndrome, Utilizing Data from the Dental, Oral, Medical Epidemiological (DOME) Cross-Sectional Record-Based Nationwide Study. <i>Biology</i> , 2021 , 10,	4.9	0
35	Relationship Between Non-Alcoholic Fatty Liver Disease and Abdominal and Pericardial Adipose Tissue in Middle-Aged and Elderly Subjects. <i>International Journal of General Medicine</i> , 2021 , 14, 3439-3444	2.3	2
34	Serum Eglutamyltransferase level is associated with periodontal disease independent of drinking habits in Japanese adults. <i>Medical Science Monitor</i> , 2014 , 20, 2109-16	3.2	22
33	Vismodegib suppresses TRAIL-mediated liver injury in a mouse model of nonalcoholic steatohepatitis. <i>PLoS ONE</i> , 2013 , 8, e70599	3.7	64
32	Performance of Serum microRNAs -122, -192 and -21 as Biomarkers in Patients with Non-Alcoholic Steatohepatitis. <i>PLoS ONE</i> , 2015 , 10, e0142661	3.7	90
31	Non-Alcoholic Fatty Liver Disease Is a Risk Factor for the Development of Diabetic Nephropathy in Patients with Type 2 Diabetes Mellitus. <i>PLoS ONE</i> , 2015 , 10, e0142808	3.7	48
30	Iron Status and Metabolic Syndrome in Patients with Non-Alcoholic Fatty Liver Disease. <i>Middle East Journal of Digestive Diseases</i> , 2016 , 8, 31-8	1.1	5
29	Pharmacological Strategies for Insulin Sensitivity in Obesity and Cancer: Thiazolidinediones and Metformin. <i>Current Pharmaceutical Design</i> , 2020 , 26, 932-945	3.3	5
28	Apolipoprotein A5: Extracellular and Intracellular Roles in Triglyceride Metabolism. <i>Current Drug Targets</i> , 2015 , 16, 1274-80	3	25
27	Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations. <i>World Journal of Gastroenterology</i> , 2014 , 20, 9330-7	5.6	223

26	Serum immunoglobulin A concentration is a reliable biomarker for liver fibrosis in non-alcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2014 , 20, 12566-73	5.6	12
25	Alimentary regimen in non-alcoholic fatty liver disease: Mediterranean diet. <i>World Journal of Gastroenterology</i> , 2014 , 20, 16831-40	5.6	77
24	Pathogenesis and therapeutic approaches for non-alcoholic fatty liver disease. <i>World Journal of Hepatology</i> , 2014 , 6, 800-11	3.4	52
23	Pre-and-post transplant considerations in patients with nonalcoholic fatty liver disease. <i>World Journal of Transplantation</i> , 2014 , 4, 81-92	2.3	19
22	Association Between LYPLAL1 rs12137855 Polymorphism With Ultrasound-Defined Non-Alcoholic Fatty Liver Disease in a Chinese Han Population. <i>Hepatitis Monthly</i> , 2015 , 15, e33155	1.8	5
21	SREBP1c silencing reduces endoplasmic reticulum stress and related apoptosis in oleic acid induced lipid accumulation. <i>Marmara Medical Journal</i> ,		
20	Carnosol alleviates nonalcoholic fatty liver disease by inhibiting mitochondrial dysfunction and apoptosis through targeting of PRDX3. <i>Toxicology and Applied Pharmacology</i> , 2021 , 432, 115758	4.6	0
19	PI3K/PTEN signaling in liver diseases. 287-313		
18	Etiology and Pathogenesis of Hepatocellular Carcinoma: Inflammatory and Toxic Causes. 2016 , 1-29		
17	Etiology and Pathogenesis of Hepatocellular Carcinoma: Inflammatory and Toxic Causes. 2017 , 2931-2959		
16	The Herbal Composition Gangjihwan from Ephedra intermedia, Lithospermum erythrorhizon and Rheum palmatum Ameliorates Hepatic Inflammation and Fibrosis in Obese C57BL/6J Mice and HepG2 Cells. <i>Biomedical Science Letters</i> , 2017 , 23, 144-153	0.3	
15	The Relationship between Insulin Resistance and Liver Damage in non-alcoholic Fatty Liver Patients. <i>Sisli Etfal Hastanesi Tip Bulteni</i> , 2020 , 54, 411-415	0.8	1
14	Dynamic PET of Human Liver Inflammation: Impact of Kinetic Modeling with Optimization-Derived Dual-Blood Input Function.		
13	Frontiers and prospects of pharmacotherapy for non-alcoholic fatty liver disease. <i>World Chinese Journal of Digestology</i> , 2019 , 27, 73-79	0.1	0
12	A Systematic Review of Gastrointestinal Manifestations in Diabetic Nephropathy. <i>Exploratory Research and Hypothesis in Medicine</i> , 2019 , 000, 1-10	1	1
11	 <i>Medical and Clinical Chemistry</i> , 2019 , 64-70	0.1	
10	Non-viral liver diseases: pathogenetic approaches to therapy. <i>Medical Alphabet</i> , 2019 , 3, 30-36	0.3	
9	Possibilities of using natural mineral waters in the treatment of patients with non-alcoholic fatty liver disease. <i>Balneo Research Journal</i> , 2019 , 10, 450-456	0.4	

8	Obstructive sleep apnea and severity of nonalcoholic fatty liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2021 , 33, 1104-1109	2.2	3
7	Intestinal mucosal barrier dysfunction participates in the progress of nonalcoholic fatty liver disease. <i>International Journal of Clinical and Experimental Pathology</i> , 2015 , 8, 3648-58	1.4	26
6	Genistein-Opportunities Related to an Interesting Molecule of Natural Origin.. <i>Molecules</i> , 2022 , 27,	4.8	1
5	Effect of Probiotics Therapy on Nonalcoholic Fatty Liver Disease. <i>Computational and Mathematical Methods in Medicine</i> , 2022 , 2022, 1-15	2.8	1
4	Chronic liver diseases and erectile dysfunction. 10,		0
3	Obeticholic Acid: Pharmacological and Clinical Review. 2023 , 3, 238-251		0
2	Application of machine learning in predicting non-alcoholic fatty liver disease using anthropometric and body composition indices. 2023 , 13,		0
1	Hepatoprotective Effect of Parijoto Fruit Extract (<i>Medinilla speciosa</i> Blume) on Male Mice Fed with High-Fat Diet. 2023 , 18, 21-30		0